Advancing excellence in laboratory medicine for better healthcare worldwide

Congresses and Conferences Committee (C-CC)

Congresses and Conferences Committee 

Hybrid meeting during 2022 WorldLab Seoul

L/R - T/B

W.H.Fang, Corresponding Member; A. Buňo Soto, Member; A.Sepici Dincel, Corresponding Member; S.Robinson, Corresponding Member; M.Blanes, Member; H.Martin, Corresponding Member; P. Laitinen, Chair

Last  picture L/R

S.Cardinale, IFCC Office; P.Laitinen, Chair; H.Martin, Corresponding Member; M.Blanes, Member

Members of C-CC Executive Committee and terms of appointment

NamePositionCountryTermTime in Office
P.LaitinenChairFI1st2021 01 - 2023 12
M. Blanes GonzalesMemberPY2nd2021 01 - 2023 12
A. Buňo SotoMemberES1st2021 01 -2023 12
C. JacksonCorporate MemberUS2nd202101 - 2023 12
A.Cano HuizarCorresponding MemberMX
W.H. FangCorresponding MemberTW
J.KumalawatiCorresponding MemberID
H. MartinCorresponding MemberAU
S.RobinsonCorresponding MemberUK
A.Sepici DincelCorresponding MemberTR
C.TsatsanisCorresponding MemberGR

C-CC Executive Committee (C-CC-EC)

The Committee on Congresses and Conferences was established in December 2007, and is the continuation of the former Congress and Conference Division (CCD) which was founded in 1996, but with an expanded charter and responsibilities. The C-CC has the major administrative and managerial responsibility within the IFCC for all meetings coordinated by the IFCC.

C-CC Mission statement

The mission of the C-CC is to provide general administration and management of all IFCC meeting activities (congresses, conferences, and symposia) and to review  applications for IFCC auspices from non-IFCC conferences requesting such sponsorship.

C-CC Strategy

The C-CC supports and promotes Clinical Laboratory Sciences through congresses, conferences, specialised meetings, and other professional meetings. The C-CC Works closely with the organisers of the various IFCC related conferences to ensure that they achieve organisational and professional excellence.


  • The C-CC formulates and updates as required the guidelines, procedures and practices for IFCC-designated meetings and also monitors  compliance throughout the planning and organizational stages. The C-CC assists the organizing groups in the administration and promotion of conferences, and helps these conferences obtain support, and achieve financial efficiency in the various economical aspects of their meetings.

  • The C-CC reviews all existing meeting guidelines every three years to ensure their continued applicability and will write new guidelines for those meetings not covered by existing procedures.

  • The C-CC maintains a current 5-year listing of congresses and conferences of professional interest to the members of the IFCC, including both IFCC related conferences and those outside the IFCC. This allows members to be aware of these meetings and allows potential conference organisers to plan the dates of their meetings with care.

  • The C-CC designates as official IFCC approved meetings those conferences that conform to the requirements of the IFCC as a professional organisation, in order to promote the field of clinical laboratory sciences and protect the interests of the IFCC. Within the framework of the IFCC designated meetings, the C-CC will  promote the IFCC and its functional units and discuss the possibility of integration     of IFCC units and members in the programme of the conference.

  • The C-CC assists in expanding the list of IFCC Master Conferences on specific scientific and educational topics and promotes the leadership role of the IFCC in the field of Clinical Laboratory Sciences.

IFCC WorldLab (International Congress of Clinical Chemistry and Laboratory Medicine, ICCCLM) 

IAmsterdam (NL)1954
IINew York (US)1956
IIIStockholm (SE)1957
IVEdinburgh (UK)1960
VDetroit (US)1963
VIMunich (DE)1966
VIIGeneva/Evian (CH/FR)1969
VIIICopenhagen (DK)1972
IXToronto (CA)1975
XMexico City (MX)1978
XIVienna (AT)1981
XIIRio de Janeiro (BR)1984
XIIIThe Hague (NL)1987
XIVSan Francisco (US)1990
XVMelbourne (AU)1993
XVILondon (UK)1996
XVIIFlorence (IT)1999
XVIIIKyoto (JP)2002
XIXOrlando (US)2005
XXFortaleza (BR)2008
XXIBerlin (DE)2011
XXIIIstanbul (TR)2014
XXIIIDurban (ZA)2017
XXIVSeoul (KR)2022
XXVRome (IT)2023
XXVIDubai (UAE)2024

IFCC Regional Congresses

Asian Pacific Federation of Clinical Biochemistry (APFCB)

IIISingapore (SG)1986
IVHong Kong (HK)1988
VKobe (JP)1991
VIMelbourne (AU)1993
VIIBangkok (TH)1995
VIIIKuala Lumpur (MY)1998
IXNew Dehli (IN)2001
XPerth (AU)2004
XIBeijing (CN)2007
XIISeoul (KR)2010
XIIIBali (ID)2013
XIVTaiwan (TW)2016
XVJaipur (IN)2019
XVISeoul (KR)2022
XVISydney (AU)2024

IFCC EuroMedLab organized with EFLM

IMunich (DE)1974
IIPrague (CZ)1976
IIIBrighton (UK)1979
IVVienna (AT)1981
VBudapest (HU)1983
VIJerusalem (IL)1985
VIIDen Hague (NL)1987
VIIIMilan (IT)1989
IXCrakow (PL)1991
XNice (FR)1993
XITampere (FI)1995
XIIBasel (CH)1997
XIIIFlorence (IT)1999
XIVPrague (CZ)2001
XVBarcelona (ES)2003
XVIGlasgow (UK)2005
XVIIAmsterdam (NL)2007
XVIIIInnsbruck (AT)2009
XIXBerlin (DE) (with ICCCLM 2011)2011
XXMilan (IT)2013
XXIParis (FR)2015
XXIIAthens (GR)2017
XXIIIBarcelona (ES)2019



Latin American Confederation of Clinical Biochemistry (COLABIOCLI) Domingo (DO)1991
Acapulco (MX)1993
Buenos Aires (AR)1995
Caracas (VE)1997
Puerto Rico (PR)1999
Florianopolis (BR)2001
San José (CR)2003
Asunciòn (PA)2006
Panama (PAN)2007
Santiago (CL)2010
Punta Cana (DO)2011
Lima (PE)2013
Quito (EC)2015
Punta del Este (UY)2017
Panama (PA)2019
Leon (MX)2022

Arab Federation of Clinical Biochemistry (AFCB)

Cairo (EG)1974
Faihaa (SY)1976
Cairo (EG)1980
Cairo (EG)1983
Cairo (EG)1986
Tunis (TN)1991
Faihaa (SY)1994
Amman (JO)1997
Rabat (MA)2000
Monastir (TU)2004
Damascus (SY)2006
Beirut (LB)2009
Marrakesh (MA)2012
Karthoum (SD)2015
Palestine (PS)2018
Broumana (LB)2022

African Federation of Clinical Chemistry (AFCC)

Ibadan (NG)2009
Nairobi (KE)2011
Harare (ZW)2015
Marrakesh (MA)2019
Lusaka (ZM)2021

IFCC Specialized Conferences

Critical Role of Clinical Laboratories in the COVID-19 Pandemic

2021 - Virtual IFCC Global Conference on COVID-19

The 2020 pandemic has highlighted the critical role of clinical laboratory medicine. Clinical laboratory professionals has playd a vital role in the diagnosis of SARS-CoV-2 infection, serological monitoring of individuals with past SARS-CoV-2 infection, and biochemical monitoring of hospitalized patients with COVID-19.
IFCC has established a Taskforce on COVID-19 to provide updates on epidemiology, pathogenesis, and diagnostics of COVID-19, as well as to develop practical recommendations for diagnostic testing and patient monitoring. Since establishment, the Taskforce has maintained an online Information Guide on COVID-19, which can be found on the IFCC website. This guide is updated biweekly, presenting the latest evidence on COVID-19.
IFCC has hosted a virtual IFCC Global Conference on COVID-19 on February 15-17, 2021. This virtual conference has brought leading experts around the world together to present the latest advances in COVID-19 diagnostics and therapeutics. The theme of this conference was the Critical Role of Clinical Laboratories in the COVID-19 Pandemic.
The program, included ten scientific symposia, covering physiology, diagnostics, therapeutics, and technology, as well as special presentations on the global response to COVID-19 in Africa, Asia-Pacific, Europe, Latin America, Arab Federation, and North America. There was an industry panel with presentations from industry leaders on the latest IVD innovations and twelve educational industry workshops. Young investigators had their own forum with presentations from young scientists worldwide. There was also an opportunity for scientific e-posters and virtual industry exhibits.

Conference organizing committee

Khosrow Adeli, CA (Chair)
Sergio Bernardini, IT
Andrea Horvath, AU
David Koch, US
Giuseppe Lippi, IT
Tomris Ozben, TR
Cheng-Bin Wang, CN
Corporate Representatives:
Rolf Hinzmann, Roche Diagnostics
Patricia Ravalico, Abbott Diagnostics
Regional Federation Representatives:
Rosa Sierra-Amor (COLABIOCLI)
Ana-Maria Simundic (EFLM)
Ann Gronowski (NAFCC)
Rajiv Erasmus (AFCC)
Sunil Kumar Sethi (APFCB)
Osama Najjar (AFCB)
Conference Organizing Secretariat (MZ Congressi):
Stefano Montalbetti

IFCC-Roche Diagnostics Bergmeyer Conferences

Goals and Objectives

  • The Bergmeyer Conferences founded in 1987 are a collaborative effort of IFCC and Roche Diagnostics focused on standardisation issues.
  • The objectives of these Conferences are:
    • Improving the Comparability and Compatibility of Laboratory Assay results in life sciences;
    • Improving the Clinical Value of Laboratory Data;
    • Discussion of Standardisation Issues and suggesting solutions in order to achieve the first two objectives;
    • Master Discussion of Experts and a Brain Storming Forum for projects to be executed by Scientific Division's Committees or Working Groups.
    • Each Conference is devoted to a rapid developing new area relevant for laboratory science and clinical medicine. The scope of a Conference is to be organised in that manner that besides comprehensive review also future trends, analytical pitfalls and the rationale, clinical use of the diagnostic procedures have to be considered.
    • These Conferences are Master Discussions of experts in the respective topic of a Conference. Participation is only possible on invitation.
    • The governing body of these Conferences is the Steering Committee consisting of IFCC (3), the editor of the proceedings (1) and Roche Diagnostics (1) representatives.
    • Conferences are held in Eibsee, Germany.
    • Lectures and contributions presented at the Conferences are published in the Conference proceedings.

    Terms of Reference

    • Organisation of Bergmeyer Conferences: selection of date and topic; responsibility for the scientific content and selection of speakers;appointment of an ad hoc Working Group (occasionally) for the preparation of draft documents to be circulated prior to the respective Conference to the participants; review of the organisational and financial commitments.
    • Review of documents produced in conjunction with each Conference;
    • Submission of documents to the Scientific Division for final approval;
    • Publication of proceedings - Appointment of editors;
    • The Proceedings are published in the Scandinavian Journal;
    • Collaboration with Roche Diagnostics and the local organising group
    • Report to Scientific Division, information to the Congresses and Conferences Committee;
    • The Membership to be nominated by SD and approved by EB. The terms of the IFCC members are usually 3 years; re-appointments are possible.

Recent Conferences:

VII1999Biochemical markers for myocardial damage
VIII2001Biochemical markers of autoimmune disease
IX2003Nucleic acid markers for bacterial and viral infections in intensive care
X2005Diabetes and cardiovascular disease
XI2008Markers of kidney disease
XII2010Novel biomarkers: from discovery to clinical application
XIII2012Vitamin D in health and disease
XIV2014Women's Health
XV2016Biomarkers in the Diagnosis and Monitoring of Cancer

European Beckman Coulter Molecular Basis of Diseases Conferences

  1. 1998 - Inflammatory Diseases
  2. 2000 - Cell Biology of Neuronal Dysfunction

Roche Molecular Biology Conferences

  1. 1998 - Recent Progress in Molecular Biology Technology
  2. 2000 - Validating and Using Pharmacogenetics

Beckman Coulter Proteins Conferences

  1. 2001 - Prague
  2. 2003 - Barcelona

Ortho Clinical Diagnostics Conferences

  1. 2008 - Birmingham - Biochemical markers in clinical cardiology: perspective from present to future
  2. 2011 - Paris - Pregnancy-related disorders

 Siemens Conference

  1. 2014 - Toronto - Biomarkers in Neuropsychiatric Disorders

 Roche Conferences

  1. 2014 - Rome - Biomarkers in Alzheimer Disease
  2. 2016 Mexico City - Biomarkers in Alzheimer Disease

Mediterranean Conference.

  1. 2018 - Rome – 1st IFCC EFLM AFCB Conference – Laboratory Medicine meeting the needs of Mediterranean Nations.

Congress Guidelines and Other Documents

The following documents have been prepared by the C-CC.

  • Auspices of the IFCC - Guidelines and Procedures
  • Guidelines for International Congresses of Clinical Chemistry and Laboratory Medicine (ICCCLM)
  • Guidelines for EFCC European Congresses of Clinical Chemistry and Laboratory Medicine (EuroMedLab)

IFCC General Conference


The aim of the IFCC General Conference is to convene all the IFCC functional units at one time and location, in order to discuss present activities and projects, and to plan and decide on future actions of the organization.


  • The Committee on Congresses and Conferences (C-CC) of the IFCC bears overall responsibility for the organization of the General Conference.
  • The IFCC Secretary is responsible for the Conference agenda.
  • The IFCC Executive Board is responsible for detailed programme content
  • The IFCC Office will carry out the administrative activities in preparing for the Conference in collaboration with the C-CC and a local organizing committee from the national society of the country where the meeting is being held.

Time and Venue

  • A General Conference is held once during the triennial term of the Executive Board (EB) of IFCC, usually during the second year. The EB decides on the time of the year at which to hold this Conference.
  • The EB will decide on the venue for the IFCC General Conference following a recommendation from the C-CC.
  • The duration of the General Conference is 2 days, and is preceded by 2 days of an EB meeting and meetings of the Divisions and Committees. This period is required to enable all the IFCC functional units to meet individually and collectively.


  • Prior to the General Conference all IFCC functional units carry out their own meetings, meet with their immediate and/or Divisional supervisors, and report on the progress of their projects and on project proposals. The Division Executive Committees then meet with the EB to present the status of their Division, and to obtain consent for future and/or continuing activities.
  • Representatives from Full Members and Corporate Members join IFCC functional units for the General Conference proper.


IRungestedgaard (DK)1981
IIRungestedgaard (DK)1984
IIIMonza (IT)1988
IVPont-à-Mousson (FR)1992
VLeipzig (DE)1995
VISevilla (ES)1998
VIIDubrovnik (HR)2001
VIIISousse (TN)2004
IXAntalya  (TR)2008
XCorfu (GR)2010
XIKuala Lumpur (MY)2012
XIIMadrid (ES)2016
XIIIBudapest (HU)2018

Committee members' contact details


Prof. Paivi LAITINEN
Adjunct Professor


Dr. Antonio BUÑO SOTO
Department of Laboratory Medicine
University Hospital La Paz
Paseo de la Castellana 261
28046 Madrid

Prof. Montserrat BLANES GONZALES
Dept.of Medical Education and Research
Central Hospital
Paraguayan Social Security Institute
Av.da Sacramento y Dr Peña
1209, Asuncion, Paraguay

Corporate Member:

Mrs. Cheryl JACKSON
Global Marketing Technology and Sales Education
Beckman Coulter Diagnostics
200 South Kraemer Boulevard
Brea, CA  92821, USA

Corresponding Members:

Prof. Woei-horng FANG
Dept of Clinical Laboratory Sciences  
and Medical Biotechnology
National Taiwan University
College of Medicine
#7 Chung-Shan South Road
Taipei 100-02,TAIWAN

M.C. Alejandra A. CANO HUÍZAR
CLEAR Consulting and Training Services
Loma Pareja 38, Bonanza
P. 58095, Morelia, Michoacán

Clinical Pathology Department
Faculty of Medicine Universitas Indonesia
Dr. Cipto Mangunkusumo Hospital
Julan Diponegoro No. 69-71
Jakarta, 10430

Ms. Helen MARTIN
Chemical PAthology
SA Pathology
1 Frome Road, Adelaide
South Australia

Consultant Clinical Biochemist,Clinical Lead Biochemistry,
Deputy Clinical Director,
North Midlands and Cheshire Pathology Services
Leighton Hospital
Middlewich Road, Crewe, Cheshire, CW1 4QJ, UK

Professor of Biochemistry
Department of Medical Biochemistry
Gazi University, Faculty of Medicine
Ankara, Turkey

Prof. Christos TSATSANIS
Professor of Clinical Chemistry,
Medical School, University of Crete
Director, Clinical Chemistry Laboratory
University  Hospital of Heraklion
Voutes, Heraklion 70013 Crete

Website developed by Insoft